What is he best known for?
The fields of study he is best known for:
- Gene
- Internal medicine
- Cancer
Alan Kenneth Burnett mainly investigates Internal medicine, Leukemia, Surgery, Myeloid leukemia and Oncology.
His research in Cytarabine, Chemotherapy, Induction chemotherapy, Survival rate and Chemotherapy regimen are components of Internal medicine.
His studies deal with areas such as Myeloid and Cumulative incidence as well as Leukemia.
Alan Kenneth Burnett has included themes like Clinical trial, Disease and Hazard ratio in his Surgery study.
His Myeloid leukemia study is concerned with the field of Cancer research as a whole.
His work carried out in the field of Oncology brings together such families of science as Acute promyelocytic leukemia, Hematology, FLT3 Internal Tandem Duplication, NPM1 and Cytogenetics.
His most cited work include:
- Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. (2438 citations)
- The Importance of Diagnostic Cytogenetics on Outcome in AML: Analysis of 1,612 Patients Entered Into the MRC AML 10 Trial (2415 citations)
- Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials (1298 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of investigation include Internal medicine, Immunology, Oncology, Myeloid leukemia and Leukemia.
His Internal medicine study combines topics from a wide range of disciplines, such as Gastroenterology and Surgery.
His Immunology research integrates issues from Progenitor cell, CD34, Haematopoiesis, Stem cell and Mutation.
His Oncology research incorporates elements of Hematology, Minimal residual disease, Gemtuzumab ozogamicin, NPM1 and Cytogenetics.
The study incorporates disciplines such as Acute promyelocytic leukemia, Disease and Fms-Like Tyrosine Kinase 3 in addition to Myeloid leukemia.
He combines subjects such as Myeloid and Survival rate with his study of Leukemia.
He most often published in these fields:
- Internal medicine (47.41%)
- Immunology (27.69%)
- Oncology (26.49%)
What were the highlights of his more recent work (between 2012-2021)?
- Internal medicine (47.41%)
- Oncology (26.49%)
- Myeloid leukemia (25.90%)
In recent papers he was focusing on the following fields of study:
His primary scientific interests are in Internal medicine, Oncology, Myeloid leukemia, Myeloid and Leukemia.
His research in Internal medicine intersects with topics in Gastroenterology, Gemtuzumab ozogamicin, Surgery and Immunology.
The various areas that Alan Kenneth Burnett examines in his Oncology study include Hematology, Myeloid leukaemia, Cumulative incidence, Minimal residual disease and NPM1.
His Myeloid leukemia research includes elements of Progenitor cell, Hematopoietic stem cell transplantation, Transplantation and Hazard ratio.
His study explores the link between Myeloid and topics such as Molecular biology that cross with problems in Wnt signaling pathway.
His Leukemia study integrates concerns from other disciplines, such as Young adult, Proportional hazards model and Bone marrow.
Between 2012 and 2021, his most popular works were:
- Assessment of Minimal Residual Disease in Standard-Risk AML. (398 citations)
- Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: A meta-analysis of individual patient data from randomised controlled trials (333 citations)
- Acute myeloid leukaemia. (262 citations)
In his most recent research, the most cited papers focused on:
- Gene
- Cancer
- Internal medicine
Alan Kenneth Burnett mainly focuses on Leukemia, Internal medicine, Myeloid, Myeloid leukemia and Oncology.
Alan Kenneth Burnett has included themes like Young adult, Protein kinase B, Protein kinase C and Pediatrics in his Leukemia study.
The Internal medicine study combines topics in areas such as Gemtuzumab ozogamicin and Surgery.
The concepts of his Myeloid study are interwoven with issues in Molecular biology, CEBPA, NPM1 and Performance status.
His biological study spans a wide range of topics, including Proportional hazards model, Survival analysis, Daunorubicin and Minimal residual disease.
His Oncology study combines topics from a wide range of disciplines, such as Immunophenotyping and Fms-Like Tyrosine Kinase 3.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
